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Introduction: Schizophrenia is a chronic mental illness with clusters of symptoms, including cognitive impairment.
This study aimed to explore the effect of Tualang Honey (TH) on cognitive domains, especially as it pertained to
the verbal memory of schizophrenia patients.
Method: This was a cross-sectional study involved 80 individuals, diagnosed with schizophrenia. The Malay
Version Auditory Verbal Learning Test (MVAVLT) was used. Data were analysed using SPSS 20.0 software.
Intention to treat analysis was applied.
Result: A comparison of the total learning score at eight weeks between the two groups based on time effect and
time-treatment interaction favoured TH group.
Conclusion: This study concludes that by supplementing schizophrenia patients with 8-week of TH did improve
total learning performance across domains in the immediate memory among patients with schizophrenia.1. Introduction
Schizophrenia is a chronic mental illness with major clusters of
symptoms, including positive symptoms, negative symptoms and cogni-
tive impairment. It is debilitating and common. It occurs in approxi-
mately 1% or nearly 21 millions of world population (WHO, 2018).
Locally, the National Mental Health Registry (NMHR) at the Ministry of
Health Malaysia reported an incidence rate of between 7.3 to 43.0 per
100 000 population (Malaysia, 2005). A weakening in at least one of the
cognitive function domain occurred in 80% of schizophrenia patients (R.
S. E. Keefe and Fenton, 2007) and cognitive impairment is a core feature.
Cognitive impairment is both predictive for functional outcomes and a
treatment target (Green et al., 2004). Cognitive dysfunction can indeed
be present before the onset of psychotic symptoms, and after the first
psychosis, it either remains at decreased levels or declines during the
illness (Kahn and Keefe, 2013). The most impaired cognitive domain is
verbal memory (Cirillo and Seidman, 2003) which is associated with a
poor functional outcome (Barch and Ceaser, 2012) and impaired exec-
utive function (Abdel-Hamid et al., 2009). The pathophysiology of
cognitive dysfunctions in schizophrenia is complex and involves many. Jusoh).
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vier Ltd. This is an open access adifferent neurotransmission systems, including the glutamatergic and
cholinergic system (R. S. Keefe et al., 2013). Cognitive enhancers have
been a primary focus of research in the last decades, and have shown
promising but inconclusive results (Sinkeviciute et al., 2018).
Honey is a sweet, viscous food substance produced by bees and some
related insects. In myths and folk medicine, honey has been used to treat
various ailments by ancient peoples and in Ayurveda and traditional
Chinese medicine. More recently, extensive studies have been conducted
on the application of honey in modern medicine. Locally, the Tualang
honey (TH), in particular, is used in diverse medical conditions based on
its many different properties. TH contains polyphenols with antioxidant
(Moniruzzaman et al., 2013), antibacterial (Nasir et al., 2010), and
antiproliferative (Nurul Syazana, Halim, Gan and Shamsuddin, 2011)
activities. It promotes wound healing (Khoo et al., 2010). A recent study
also showed that TH ameliorated impaired immediate memory among
postmenopausal women (Othman et al., 2011) and reduced anxiety in
rats (B. Al-Rahbi et al., 2013). It is hypothesised that TH has a role in
improving learning and memory via (i) a reduction of oxidative stress,
(ii) an enhancement of the cholinergic system, (iii) an induction of the
synthesis and secretion of brain-derived neurotrophic factor (BDNF) and5 May 2020
rticle under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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study aimed to explore the effect of TH on cognitive domains, especially
as it pertained to the verbal memory of schizophrenia patients.
2. Materials and methods
2.1. Study subjects
The study involved 80 individuals, aged 18–55 years, diagnosed with
schizophrenia who were attending the psychiatry outpatient clinic at
Hospital Universiti Sains Malaysia (HUSM) and fulfilled the inclusion and
exclusion study criteria (Table 1) were consecutively invited to enrol in
this study.
Sociodemographic data and personal details of the patients including
age, gender, ethnicity, marital and employment status, educational level,
religion, number of hospitalisation, the overall duration of illness,
treatment and type of pharmacotherapy were recorded. Eligible patients
were randomly assigned to control and intervention groups by block
allocation randomisation.
The TH was obtained from the Federal Agriculture Marketing Au-
thority (FAMA) in sachet form. Each sachet consisted of 20 g TH. FAMA
did the processing steps from harvesting, sterilising and packaging based
on its standard protocol. The physiochemical and safety characteristic
were analysed and validated by a GMP certified laboratory. Forty "con-
trol" subjects continued their prescribed medical treatment without
honey, and another 40 were maintained on their medical treatment to
which was added eight-week supplies of TH to be consumed at 20gm
daily, every morning at 8.00 am. The honey was supplied in sachets every
fortnightly. Empty sachets were exchanged with new sachets, and their
daily honey intake was monitored by relatives to ensure compliance.
Ethical approval was obtained from the Human Research and Ethics
Committee, School of Medical Sciences, Universiti Sains Malaysia
(HREC), study protocol code USM/JEPeM/140355. Informed consent
was obtained from all study subjects before the study commenced.2.2. Research tools
The Malay Version of Auditory Verbal Learning Test (MVAVLT)
(Ruzita Jamaluddin et al., 2009) was used to evaluate short-term mem-
ory, to retain and recall information after some impediment. The tool was
translated from World Health Organization/the University of California,
Los Angeles (WHO/UCLA) version of the Auditory Verbal Learning Test
(Maj et al., 1993; Rey, 1958) and yielding a Cronbach alfa value of 0.84,
and test-retest correlations ranged from 0.24 to 0.84 (Ruzita Jamaluddin
et al., 2009). There were two distinct series of items to be recognised
comprising of List A, List B, together with a Recognition List. Each series
consisted of 15 concrete nouns which are commonly used in local con-
versation across all ages group.
The test affords the ability of a person to encode, consolidate, store,
and retrieve verbal information, and is usually applied using a five-trial
presentation of a 15-noun word list (list A) (presentation rate of one
word per second), a single presentation of a 15-noun word interferenceTable 1. Inclusion and exclusion study criteria.
Inclusion Criterias Exclusion Crit
 Schizophrenia patient according to the (DSM-5)  Cognitive d
 BPRS score <30  Substance in
 Able to speak understand Malay language  Intellectual
 Neurocogni
 Medical con
 Severe com
 Regular ben
Diagnostic and Statistical Manual of Mental Disorders, 5th edition (DSM-5), Brief Psy
2list (list B), two post-interference recall trials—one immediate, one
delayed (ranging from 20 to 45 min, most commonly around 30 min) and
a recognition trial of 50 words containing the target words of lists A and B
and 20 distractor words phonetically or semantically similar to those in
lists A and B (M.D. Lezak, 2004; Schmidt, 1996). The listed words were
documented before the study to ensure consistency.
A trained enumerator or the researcher conducted the test. Inter-rater
reliability analysis showed high agreement between the ratters in the first
exposure of the evaluation with 97.3%.
BPRS (Overall and Gorham, 1962) was also applied to assess psy-
chotic symptoms. BPRS consisted of 18-symptoms constructs that took
20–30 min for the assessment and scoring. Evaluations were adminis-
tered at week 0 (pre-) and repeated at week 8 (post-intervention) of the
two-month follow-up period.
2.3. Data analysis
Data were analysed using SPSS 20.0 software (supplier). Intention to
treat analysis was applied. Results are presented as means and standard
deviations (SD), or medians and interquartile ranges (IQR), or as per-
centages (%), as appropriate. Univariate analyses were performed to
compare baseline characteristics between control and intervention
groups. Independent t-test was applied for numerical variables. Pearson
chi-square test was used for categorical variables. Repeated measures
analysis of covariance (RmANCOVA) was applied to analyse dependent
variables, total learning and delayed recall scores of MVAVLT with two
levels of measurements: before intervention (pre) at week 0 and after
intervention (post) at week 8. All statistical tests were two-sided, and P<
0.05 was considered to indicate statistical significance.
3. Results
Eighty subjects met the criteria and were consented and randomised
into control and TH groups. There were no significant differences in
sociodemographic and clinical characteristic between the groups at
baseline (Table 1) (see Figure 1).
A comparison of the total learning score between the two groups
based on time (time effect) favoured TH group. The TH group demon-
strated a significantly higher mean total score compared to the control
group at eight weeks (2.40; 95%CI:0.53,4.27 vs 0.38; 95%CI:1.00,1.75
(Table 2).
Similarly, a significantly higher mean score was observed compared
with the control group (time-treatment interaction) 28.86; 95%CI: 25.13,
32.23 vs 24.69; 95%CI: 21.14, 28.24 (F ¼ 4.46, p ¼ 0.038) (Table 3).
Otherwise, there was no interaction between the groups (Table 4)
(see Table 5).
Repeated measure ANCOVA between-group analysis with regard to
time was applied. Binary covariate (age, education duration and illness
duration) was controlled by using repeated measure ANCOVA.
Assumption normality, homogeneity of variances, compound symmetry
and homogeneity of regression were checked and were fulfilled.erias
isorder such as delirium and dementia
toxication or withdrawal
disabilities
tive impairment
dition that affected with intervention substances such as diabetes mellitus or acromegaly.
munication problems such as deafness and mute
zodiazepine or anticholinergic medications
chiatric Rating Scale (BPRS).
Figure 1. (a): Total learning score and (b): Delayed recall scores of MVAVLT performance in control group (n ¼ 40), and honey group (n ¼ 40) at pre-intervention and
intervention. The differences between pre-intervention and post-intervention scores for each group were analysed using RM ANCOVA. Covariates appearing in the
model are evaluated at the following values: Age in years ¼ 30.98, Education in years ¼ 12.66, Overall duration of illness in months ¼ 107.68. MVALVLT, Malay
version of the Auditory Verbal Learning Test, RM ANCOVA, Repeated measure analysis of covariance.
Table 2. Socio-demographic and clinical characteristics of subjects (n ¼ 80).
Characteristic TH group (n ¼ 40) Control group (n ¼ 40) p-value
Mean (SD) Frequency (%) Mean (SD) Frequency (%)
Age in years 31.43 (8.68)a 30.53 (7.89) 0.629c
Age at first treatment (years) 22.05 (7.55)a 22.70 (6.82) 0.688c
Sex 0.370b
Male 21 (55.3) 17 (44.7)
Female 19 (45.2) 23 (54.8)
Marital status 0.533b
Single 12 (57.1) 9 (42.9)
Married 3 (60.0) 2 (40.0)
Divorced/Separated 2 (100.0) 0 (0.0)
Employment 0.937b
Unemployed 19 (46.3) 22 (53.7)
Employed 21 (55.3) 17 (44.7)
Educational (years) 12.70 (2.52) 12.63 (2.20) 0.888c
Duration of illness (months) 112.65 (86.82)a 92 (66.30) 0.235c
Duration of treatment (months) 119.55 (86.88)a 95.80 (66.18) 0.173c
Admission 0.237b
Never been admitted 11 (40.7) 16 (59.3)
At least admitted once 29 (54.7) 24 (45.3)
Antipsychotic 0.260b
Atypical 22 (46.8) 25 (53.2)
Typical 15 (62.5) 9 (37.5)
Both 3 (33.3) 6 (66.7)
a Median (IQR).
b Chi-square test.
c Independent t test.
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In recent years, there has been renewed interest in the use of natural
products to prevent and treat diseases and honey is no exception, espe-
cially with the many good testimonies of its usefulness. Its usefulness in
difficult-to-treat diseases like schizophrenia would, therefore, be
welcome, especially with laboratory and clinical evidence. This study
was prompted by observations that increased oxidative stress was asso-
ciated with a decline in executive function in healthy individuals, Alz-
heimer's patients and postmenopausal women (Doshi and Agarwal, 2013;
Hajjar et al., 2018; Hatanaka et al., 2015). Indeed, there has been a
growing interest among researchers on antioxidants (Moniruzzaman3et al., 2013; Nasir et al., 2010; Nguyen et al., 2019) in many kinds in
health and diseases. In the study of postmenopausal women, TH was
associated with a reduction in oxidative stress as evidenced by an
elevation of plasma antioxidant activities and decreased plasma lipid
peroxidation level (Shafin et al., 2014). TH consumption enhances
defence against oxidative stress and attenuates free radical-mediated
molecular destruction. This mechanism leads to improved arrangement
and number of Nissl positive cells in the mPFC and hippocampal neurons
(Badria al-rahbi, Zakaria, Othman, Hassan and Ahmad, 2014).
Our results showed that TH improved WM in the studied schizo-
phrenic subjects. There were significant differences in learning scores
according to time effect and time-treatment interaction when controlled
Table 3. Comparison of MVALT score Trials within each treatment group based on time (Time effect).
Comparison Control Honey
MD (95% CI) p- value MD (95% CI) p- value
Total learning
Pre-Post Total (A1 þ A2 þ A3 þ A4 þ A5) 0.38 (1.00,1.75) 0.584 2.40 (0.53, 4.27) 0.013*
Delayed recall
Pre- Post A7 0.25 (0.07,0.57) 0.122 0.33 (0.05,0.70) 0.085
Repeated measure ANCOVA within-group analysis was applied followed by pairwise comparison with confidence interval adjustment (Bonferroni correction), Binary
covariate (age, education duration and illness duration) was controlled by using repeated measure ANCOVA.
MD ¼ mean difference.
Table 4. Comparison of MVALT score Trials among two treatment group based on time (Time treatment interaction).
Trials Time Treatment Group Mean Score 95% CI F- stat (df) p-value
Total Learning scores
(A1 þ A2 þ A3 þ A4 þ A5) Pre-treatment Control 24.50 21.42, 27.59 4.46 (1) 0.038*
Honey 26.10 23.01, 29.18
Post-treatment Control 24.69 21.14, 28.24
Honey 28.68 25.13, 32.23
Delayed Recall scores
A7 Pre-treatment Control 4.37 3.47, 5.26 0.31 (1) 0.582
Honey 4.98 4.09, 5.88
Post-treatment Control 4.58 3.68, 5.49
Honey 5.34 4.44, 6.25
A6 scores do not contribute to outcome interpretation.
Table 5. Mean difference of MVALT score trials among two (between-group).
Trials Comparison Mean Score difference (95% CI) F-stat (df) P-value
Total learning
A1þA2þA3þA4þA5 Control- Honey 2.79 (1.80,17.38) 1.46 (1) 0.230
Delayed Recall
A7 Control- Honey 0.69 (0.571,1.95) 1.19 (1) 0.280
A6 scores do not contribute to outcome interpretation.
Repeated measure ANCOVA between-group analysis was applied, followed by pairwise comparison.
Binary covariate (age, education duration and illness duration) was controlled by using repeated measure ANCOVA.
Level of significance was set at 0.05 (two-tailed).
R. Yahaya et al. Heliyon 6 (2020) e03948for covariates such as age, education and duration of illness between the
intervention group and the control group. TH supplementation for eight
weeks was associated with improvement in the total learning (immediate
memory/STM) and but not with delayed recall (LTM) in our subjects,
findings similar to studies among postmenopausal and dementia patients
(Al-Himyari, 2009; Othman et al., 2011).
Performance on WM tasks depends on dopamine function in the
dorsolateral prefrontal cortex with the cholinergic system exerting a
neuromodulatory influence on glutamatergic and GABAergic networks
(Arnsten et al., 2012). The cholinergic system in the nervous system is
critical for memory formation (Deiana et al., 2011). This is evidenced by
the shrinkage and degeneration of basal forebrain neurons alongside the
reduction of cholinergic markers in cortical and hippocampal targets in
patients with Alzheimer's disease (Schliebs and Arendt, 2011). In a study
by Al-Himyari (2009), honey was found to be protective against de-
mentia (Al-Himyari, 2009). Furthermore, an animal study showed
increased acetylcholine (ACh) and reduced acetylcholinesterase (AChE)
concentrations in stressed ovariectomised rats fed with TH. TH supple-
mentation was shown to exert beneficial effects on the medial prefrontal
cortex (mPFC) and the cholinergic system comparable to the effect of
17β-oestradiol treatment (Badria al-rahbi et al., 2014). Since TH is rich in
flavonoids and contains the highest total phenolic content compared to4other types of honey, TH may exert its positive effects through both its
antioxidant properties as well as through its effects on choline and ACh
contents (Khalil et al., 2011).
It is interesting also to postulate that TH antioxidant, and anti-
inflammatory properties (Moniruzzaman et al., 2013) together with its
effects on BDNF probably also played some roles, probably linked to
cholinergic abnormalities in schizophrenia (Sinkeviciute et al., 2018). TH
is a phytoestrogen-rich in flavonoids, substances shown to increase hip-
pocampal BDNF levels. BDNF belongs to the neurotrophin family that is
secreted in the highest amount in the brain. It plays a vital role in
long-term hippocampal potentiation linked to learning andmemory (Leal
et al., 2015). Siuda et al. found that low serum BDNF was associated with
cognitive impairment and neurodegenerative disease (Siuda et al., 2017).
TH or E2-treated stressed ovariectomised rats also showed reduced
serum adrenocorticotropic hormone and cortisone levels and
depressive-like behaviour in stressed ovariectomised rats (B. Al-Rahbi
et al., 2013).
Memory can be categorised based on temporal durabilities such as
long-term or short-term memory, or according to the content of infor-
mation and circuitry such as declarative (explicit) or non-declarative
(implicit). Short-term memory (STM) refers to the capability of retain-
ing quick information over a specified period. Working memory (WM)
R. Yahaya et al. Heliyon 6 (2020) e03948refers to the ability to coordinate or manoeuvre and retain the informa-
tion (transiently stored) during cognitive activities (Camina and Guell,
2017). Cognitive impairment in WM was demonstrated in schizophrenia
patients across all verbal memory, visuospatial and executive working
memory (Forbes et al., 2009).
This study is being carried out in light of the promising results on TH
supplementation as a cognitive enhancer. However, it is also pertinent to
highlight some limitations in this study. Firstly, the sample size is
considered small. It is imperative to design the research with a larger
sample size if we are dealing with the outcome measures such as a
cognitive performance from this particular study population. Secondly, a
brief intervention with a total duration of the 8-week supplementation
period may influence the result of the study. Hence, future long-term
study with larger sample size is needed to accurately investigate the
possible effects of Tualang honey as cognitive enhancer among schizo-
phrenia patients.
5. Conclusion
This study concludes that by supplementing schizophrenia patients
with 8-week of TH did improve total learning performance across do-
mains in the immediate memory but not in long-term memory among
patients with schizophrenia. It showed a promising role of TH which are
a natural substance, readily available and cost-effective as a cognitive
enhancer in a schizophrenic patient. The future direction of the study
should address on other cognitive domains, preferably with longer
duration of intervention and larger sample size.
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